42450-33-9

Usage

Uses

Used in Chemical Industry:
4,5-dichloro-2-(methylamino)aniline is used as an intermediate for the production of dyes and pigments due to its chemical properties and reactivity.
Used in Pharmaceutical Industry:
4,5-dichloro-2-(methylamino)aniline is used as a building block for the synthesis of various organic compounds, which can be further utilized in the development of pharmaceuticals.
Used in Research and Development:
4,5-dichloro-2-(methylamino)aniline is used in research and development for the study of its chemical properties and potential applications in various fields.
Safety Precautions:
Due to its potential health and environmental risks, 4,5-dichloro-2-(methylamino)aniline is considered a hazardous chemical. Exposure to DCMA can cause irritation to the skin, eyes, and respiratory system, and may also have harmful effects on aquatic organisms. Proper safety measures and protective equipment should be used when working with this chemical.

InChI:InChI=1/C7H8Cl2N2/c1-11-7-3-5(9)4(8)2-6(7)10/h2-3,11H,10H2,1H3

Upstream product

• 6641-64-1 4,5-dichloro-2-nitroaniline 
• 2339-78-8 1,2-dichloro-4-fluoro-5-nitrobenzene 
• 107342-18-7 4,5-dichloro-N-methyl-2-nitrobenzenamine 

Downstream Products

• 1351646-62-2 C₂₄H₁₇Cl₂F₃N₈O₂ 
• 859877-04-6 methyl 4-[(5,6-dichloro-3-methyl-2-{[4-(trifluoromethoxy)phenyl]imino}-2,3-dihydro-1H-benzimidazol-1-yl)methyl]-N-1H-tetrazol-5-ylbenzoate 
• 1351646-61-1 C₂₄H₁₈Cl₂F₃N₃O₃ 

Relevant academic research and scientific papers

Unsymmetrically-Substituted 5,12-dihydrodibenzo[b,f][1,4]diazocine-6,11-dione Scaffold—A Useful Tool for Bioactive Molecules Design

Unsymmetrically N-substituted and N,N’-disubstituted 5,12-dihydrodibenzo [b,f][1,4]diazocine-6,11-diones were synthesized in the new protocol. The desired modifications of the dibenzodiazocine scaffold were introduced at the stages of proper selection of building blocks as well as post-cyclization modifications with alkylation or acylation agents, expanding the structural diversity and possible applications of synthesized molecules. The extension of developed method resulted in the synthesis of novel: tricyclic 5,10-dihydrobenzo[b]thieno[3,4-f][1,4]diazocine-4,11-dione scaffold and fused pentacyclic framework possessing two benzodiazocine rings within its structure. Additionally, the unprecedented rearrangement of 5,12-dihydrodibenzo[b,f][1,4]diazocine-6,11-diones to 2-(2-aminophenyl)isoindoline-1,3-diones was observed under the basic conditions in the presence of sodium hydride for secondary dilactams. The structures of nine synthesized products have been established by single-crystal X-ray diffraction analysis. Detailed crystallographic analysis of the investigated tri- and pentacyclic systems has shed more light on their structural features. One cell line derived from non-cancerous cells (EUFA30—human fibroblasts) and three tumor cells (U87—human primary glioblastoma, HeLa—cervix adenocarcinoma, BICR18—laryngeal squamous cell carcinoma) were used to determine the cytotoxic effect of the newly synthesized compounds. Although these compounds showed a relatively weak cytotoxic effect, the framework obtained for 5,12-dihydrodibenzo[b,f][1,4]diazocine-6,11-dione could serve as a convenient privilege structure for the design and development of novel bioactive molecules suitable for drug design, development and optimization programs.

METHODS USING HDAC11 INHIBITORS

The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

CYCLIC GUANIDINES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

The present invention relates to cyclic guanidines, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.

Efficient solution phase synthesis of 2-(N-acyl)-aminobenzimidazoles

An efficient solution phase protocol for the synthesis of 2-(N-acyl)-aminobenzimidazoles is reported. The 2-(N-acyl)-aminobenzimidazole ring system was assembled using SNAr reactions, nitro group reduction, acylthiourea formation and cyclization with EDC. The acyl protected 2-aminobenzimidazole derivatives were obtained in high yield and purity without purification of intermediates or final products. This reaction sequence eliminates the use of highly toxic cyanogen bromide, a reagent commonly used to prepare the 2-aminobenzimidazole ring system.

Synthesis and antiparasitic activity of 2-(Trifluoromethyl)benzimidazole derivatives

2-(Trifluoromethyl)benzimidazole derivatives substituted at the 1-, 5-, and 6-positions have been synthesized and in vitro tested against the protozoa Giardia lamblia, Entamoeba histolytica, and the helminth Trichinella spiralis. Results indicate that all the compounds tested are more active as antiprotozoal agents than Albendazole and Metronidazole. One compound (20) was as active as Albendazole against T. spiralis. These compounds were also tested for their effect on tubulin polymerization and none inhibited tubulin polymerization.

Linear free energy substitutent effect on flavin redox chemistry

A systematic study on the effect of various substituents at the 7- and/or 8-position on the redox properties of isoalloxazines (flavins) is reported. The redox properties of these flavin derivatives were studied by cyclic voltammetry in 100 mM, pH 7.4 HEPES and 200 mM, pH 10 borate buffers. The magnitude and direction of the effect was dependent on the nature and location of the substituent. The redox potentials of the substituted flavins were correlated with the Hammett σ value of the substituents.